The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Size Of The Conjugate Vaccine Market In 2026 And How Much Will It Reach By 2030?
The conjugate vaccine market has experienced substantial expansion in recent years. Its value is projected to rise from $21.26 billion in 2025 to $23.84 billion in 2026, reflecting a compound annual growth rate (CAGR) of 12.1%. The historical growth of this market is attributable to government-led immunization initiatives, high prevalence of bacterial infections, support from global health organizations, proven efficacy of conjugate vaccines, and an increasing pediatric population.
The conjugate vaccine market is projected to experience swift expansion in the coming years. Its size is forecast to reach $38.54 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 12.8%. This anticipated growth is linked to factors such as increased demand for combination vaccines, the widening scope of adult vaccination initiatives, greater investment in vaccine research and development (R&D), a stronger emphasis on combating antimicrobial resistance, and enhancements in cold chain infrastructure. Key trends expected during this period involve the expansion of pediatric immunization programs, the increasing uptake of multivalent conjugate vaccines, a heightened focus on sustained immunogenicity, the proliferation of public-private collaborations in vaccine development, and innovations in carrier protein technologies.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp
What Major Growth Factors Are Impacting The Conjugate Vaccine Market?
The increasing occurrence of infectious illnesses is projected to fuel expansion in the conjugate vaccine market. These illnesses are conditions stemming from harmful microorganisms like bacteria, viruses, parasites, or fungi, capable of spreading directly or indirectly among individuals, from animals to humans, or via environmental factors. Conjugate vaccines are vital in preventing specific bacterial infectious diseases, particularly among susceptible groups such as babies and toddlers. For example, data from the Centers for Disease Control and Prevention, a government body in the US, shows that tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, signifying a jump of 1,295 cases. Furthermore, the rate of incidence also went up from 2.5 per 100,000 individuals in 2022 to 2.9 in 2023. Consequently, the growing frequency of infectious diseases is stimulating the expansion of the conjugate vaccine market.
How Is The Conjugate Vaccine Market Structured Across Different Market Segments?
The conjugate vaccine market covered in this report is segmented –
1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine
2) By Pathogen: Bacterial, Viral
3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid
4) By Patient: Pediatric, Adults
5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users
What Trends Are Driving Changes In The Conjugate Vaccine Market?
Leading companies in the conjugate vaccine market are concentrating on developing advanced next-generation conjugate vaccines to ensure more comprehensive protection against numerous pneumococcal serotypes, thereby lessening the disease burden among vulnerable populations. These next-generation conjugate vaccines function by attaching bacterial polysaccharides to carrier proteins to enhance the immune response, particularly in infants and immunocompromised individuals, offering superior protection, extended immunity, and increased effectiveness compared to traditional vaccines. For instance, in August 2025, Pfizer Ltd., an India-based pharmaceutical company, rolled out its next-generation 20-valent Pneumococcal Polysaccharide Conjugate Vaccine (Adsorbed) I.P., PCV20, for adults in India, thereby strengthening its conjugate vaccine portfolio by providing broader protection against pneumococcal disease and supporting improved public health outcomes.
Who Are The Prominent Players Across The Conjugate Vaccine Market?
Major companies operating in the conjugate vaccine market are Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus
Access The Complete Conjugate Vaccine Market Report:
https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report
Which Geographic Region Represents The Largest Conjugate Vaccine Market Share?
North America was the largest region in the global conjugate vaccine market in 2025. The regions covered in the conjugate vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Conjugate Vaccine Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp
Browse Through More Reports Similar to the Global Conjugate Vaccine Market 2026, By The Business Research Company
Conjugate Vaccine Market Report 2026
https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report
Vaccine Adjuvants Market Report 2026
https://www.thebusinessresearchcompany.com/report/vaccine-adjuvants-global-market-report
Vaccines Market Report 2026
https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model